SEC EDGARAUG 52 min read$TEM

Fukushima Ryan sold $1.1M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 23,818 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $46.19 ($43.25–$46.94, $1.10M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Fukushima Ryan

Published Aug 5, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TEM

Neutral

medium confidence

Mentioned

$TEM

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TEMNeutralLow

Why it matters

The newest disclosed fact is the $1.10M open-market sale executed across five trades on 2026-08-03 under a pre-arranged 10b5-1 plan, filed on 2026-08-05.

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is routine 10b5-1 selling with no accompanying operational or financial update.

What to watch

The filing notes indirect holdings and post-transaction share count, but provides no rationale for the sale; without follow-on buys or guidance changes, trading impact is likely limited.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05, covering sales executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction report for Tempus AI, Inc. (TEM) by CEO, Data Fukushima Ryan.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMNeutralMedium confidence

Context

Tempus AI CEO Fukushima Ryan sold $1.10M of TEM shares via a 10b5-1 plan, with weighted-average prices $46.19 across five trades.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity management rather than bearish expectations, so any price reaction may be overstated.

Key entities

issuer
Tempus AI, Inc.
Subject of the Form 4 insider sale disclosure (TEM).
insider
Fukushima Ryan
CEO, Data who executed the indirect open-market sale under a 10b5-1 plan.

Read at source ← All news

SEP 17

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min

SEP 17

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min

SEP 15

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min

SEP 5

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min

SEP 2

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min